Message Font: Serif | Sans-Serif
 
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next
Author: starck Add to my Favorite Fools Ignore this person (you won't see their posts anymore) Number: of 242  
Subject: U.S. Market Launch of Urinalysis Product Date: 8/17/2000 12:53 AM
Post New | Post Reply | Reply Later | Create Poll Report this Post | Recommend it!
Recommendations: 0
FYI... for all of you (if you're still there...)


Sunday August 16, 04:00 AM Eastern time
Company Press Release

SOURCE:Quidel Corporation


Quidel Announces U.S. Market Launch of Urinalysis Product

SAN DIEGO, Aug. 16 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL) announced today the market introduction of its new QuickVue(R) UrinChek(TM) 10 SG urine test strips in the United States. This product, currently marketed in Europe under the Rapignost(R) brand name, offers healthcare providers a quick, simple-to-use diagnostic test to assist a physician in assessing the health of a patient. Designed specifically to simplify visual test result reading, the QuickVue UrinChek test strips chemically analyze a specimen to detect the presence of ten important health markers that assist in the diagnosis of diabetes, liver and kidney disease, urinary tract infection and other ailments.

"The U.S. launch of our urinalysis test strip product provides an entry into a substantial diagnostic market and expands the popular QuickVue line of high-quality, easy-to-use, point-of-care diagnostic products. This technology offers several improvements over other products on the market today," said Lin Tanner, Senior Vice President, Global Commercial Operations. "We believe the UrinChek product will be well received by healthcare professionals and expect it to begin contributing to profits later this year."

The QuickVue UrinChek 10 SG tests for or measures the level of the following compounds in a urine specimen: bilirubin, urobilinogen, ketones, glucose, protein, blood, pH, nitrite, leukocytes, specific gravity and ascorbic acid. An important innovation in the QuickVue urinalysis strips is the test for the presence of ascorbic acid (vitamin C) in the patient's specimen. Scientific evidence overwhelmingly indicates vitamin C inhibits color development on urine test strips for glucose, blood, nitrite and bilirubin. With the QuickVue test strips, healthcare providers can detect the presence of ascorbic acid in urine and are alerted to the possibility of a false negative result. "We believe this additional test is particularly important with the increasing popularity of vitamin C supplements," stated Stephen C. Biby, Marketing Manager.

Quidel is a market leader in point-of-care, rapid diagnostics providing simple, accurate and cost-effective tests to physicians and/or consumers. QDEL's Test and Treat products are easy to use and provide results in minutes, facilitating rapid treatment, improved health outcomes, reduced costs, and increased patient satisfaction. Its core products address issues relating to a woman's health throughout her life including reproductive status, pregnancy management and osteoporosis. The company also provides diagnostic products for all family members for common health problems and infectious diseases, including influenza A and B, strep throat, H. pylori infection (peptic ulcers), chlamydia and mononucleosis. Quidel's products are sold to healthcare professionals for use in physicians' offices, clinical laboratories, pharmacies, and wellness screening centers. Quidel also manufactures a line of products sold to consumers through organizations that provide store branded products.

This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results such that actual results and performance may differ materially. Quidel's financial condition and operating results may also be materially and adversely affected by a number of factors, including, without limitation, the company's ability to successfully introduce new products and the speed of market acceptance for its products, manufacturing and deliver capabilities, adverse changes in competitive and economic conditions, or regulatory actions affecting the company, product or industry. Please see the discussion of these and other factors in Quidel's annual reports on Form 10-K and subsequent quarterly reports on Form 10-Q. For more information, please visit Quidel's web site at http://www.quidel.com

Post New | Post Reply | Reply Later | Create Poll Report this Post | Recommend it!
Print the post  
UnThreaded | Threaded | Whole Thread (1) | Ignore Thread Prev | Next

Announcements

Foolanthropy 2014!
By working with young, first-time moms, Nurse-Family Partnership is able to truly change lives – for generations to come.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Post of the Day:
Macro Economics

Looking at Currency Ratios
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and "#1 Media Company to Work For" (BusinessInsider 2011)! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement